Bisphosphonates and the dental patient: Part 2.
With the increased popularity of bisphosphonate therapy for a variety of medical conditions, it is likely, even inevitable, that all dental practitioners will encounter patients on these medications. The purpose of this article is to acquaint the reader with possible treatment options for patients on bisphosphonate therapy, both oral and intravenous. This article will build on the reader's knowledge obtained from part 1, which was published in the August 2007 issue of the Compendium.
Zak
Michael
M
Spina
Anthony M
AM
Spinazze
Russell P
RP
Perkinson
William L
WL
Spinazze
Dennis J
DJ
D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D010020:Osteonecrosis / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D010166:Palliative Care; D010455:Peptides / Q000097:blood
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide